Production of a streptomycin-Park nucleotide complex by Streptomyces griseus.

Antimicrobial Agents and Chemotherapy
I SzabóZ Dinya

Abstract

A compound (compound X) with antibacterial activity was isolated from early-exponential-phase cultures of the streptomycin producer Streptomyces griseus and from protoplast cultures of the same strain. The protoplast cultures produced a larger amount of compound X than did the young hyphae. Both the mycelia and the protoplasts incorporated 14C-labeled myo-inositol, a precursor of streptomycin, into compound X, which has an amino acid content related to that of the cell wall peptidoglycan of the producer strain. Compound X may contain a streptomycin molecule covalently bound to a cell wall precursor unit, i.e., to a Park nucleotide (J. T. Park, J. Biol. Chem. 194:897-904, 1952), through the glutamic acid of the pentapeptide component.

References

Apr 21, 1975·Biochemical and Biophysical Research Communications·H RistowH Kleinkauf
Mar 1, 1977·Antimicrobial Agents and Chemotherapy·G Y Barabas, G Szabó
Oct 1, 1976·The Journal of Antibiotics·D Gottlieb
Aug 1, 1985·Applied and Environmental Microbiology·I SzabóG Barabás
Feb 1, 1974·Journal of General Microbiology·M OkanishiH Umezawa

❮ Previous
Next ❯

Citations

Jan 1, 1990·Archives of Microbiology·I SzabóJ Barabás
Jan 14, 2010·Environmental Microbiology·Paris LaskarisLiz Wellington
Dec 3, 2008·The Journal of Chemical Physics·Aliaksandr V KrukauAndreas Savin
Jun 24, 2008·The Journal of Chemical Physics·Pascal Krause, Tillmann Klamroth
Jul 28, 2007·The Journal of Chemical Physics·Pascal KrausePeter Saalfrank

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.